Physician Perceptions and Prescribing Patterns of Once-weekly Trelagliptin in the Management of Type 2 Diabetes Mellitus: A Cross-sectional Questionnaire-based Survey Across India
International Journal of Clinical Metabolism and Diabetes · 2026-04 · 2 (1) · 25-33
DOI: 10.1177/30502071261433306 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift International Journal of Clinical Metabolism and Diabetes, online erschienen am 03.04.2026. Verfasst von Harsh J. Shah und 4 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder with increasing prevalence in India, imposing significant morbidity and healthcare burden. Dipeptidyl peptidase-4 inhibitors (DPP-4i) are established glucose-lowering agents, and Trelagliptin, a novel once-weekly DPP-4i, offers potential advantages in adherence and convenience. However, real-world evidence on its use in routine clinical practice remains scarce.
Objectives
To evaluate physician perceptions, prescribing patterns, and clinical experience with Trelagliptin in the management of T2DM in India.
Methods
A multicentre, questionnaire-based survey was conducted among 71 practicing medical professionals across diverse domains in India. The structured questionnaire captured respondents’ demographics, patient load and perceptions of glycaemic control, adherence, tolerability, safety, cost-effectiveness, and factors influencing Trelagliptin prescription. Descriptive statistics were used to analyse responses.
Results
The results demonstrated that most of the respondents were consultant physicians (64.79%), followed by diabetologists/endocrinologists (18.31%) and other specialities (16.90%). Most respondents (70.42%) identified patients with poor adherence to daily medication as suitable candidates for Trelagliptin. Physicians perceived improved glycaemic control and adherence with Trelagliptin, as rated by 90.14% and 94.37% of respondents, respectively. Additionally, 32.39% of respondents perceived Trelagliptin as superior for glycaemic control, while 70.42% perceived higher adherence and 66.20% perceived greater cost-effectiveness compared with other DPP-4i. A majority of respondents (64.79%) emphasised the importance of reducing pill burden. Improved tolerability was rated by 97.18% of respondents.
Conclusion
Based on physician perceptions, once-weekly Trelagliptin was considered a safe, effective, and convenient therapeutic option for T2DM, with respondents reporting perceived improvements in adherence and patient-centred care in routine clinical practice.
Zitieren
APA
Shah, H. J., Pariyani, J. K., Shinde, K. V., Pandya, D. P., & Dave, B. A. (2026). Physician Perceptions and Prescribing Patterns of Once-weekly Trelagliptin in the Management of Type 2 Diabetes Mellitus: A Cross-sectional Questionnaire-based Survey Across India. International Journal of Clinical Metabolism and Diabetes, 2(1), 25-33. https://doi.org/10.1177/30502071261433306
Vancouver
Shah HJ, Pariyani JK, Shinde KV, Pandya DP, Dave BA. Physician Perceptions and Prescribing Patterns of Once-weekly Trelagliptin in the Management of Type 2 Diabetes Mellitus: A Cross-sectional Questionnaire-based Survey Across India. International Journal of Clinical Metabolism and Diabetes. 2026;2(1):25-33. doi:10.1177/30502071261433306
BibTeX
@article{Shah2026,
author = {Shah, Harsh J. and Pariyani, Jacky K. and Shinde, Kalyani V. and Pandya, Dharmil P. and Dave, Bhakti A.},
title = {Physician Perceptions and Prescribing Patterns of Once-weekly Trelagliptin in the Management of Type 2 Diabetes Mellitus: A Cross-sectional Questionnaire-based Survey Across India},
journal = {International Journal of Clinical Metabolism and Diabetes},
year = {2026},
volume = {2},
number = {1},
pages = {25--33},
doi = {10.1177/30502071261433306}
}
EUVIMED